A Prospective, Non-randomized, Multicenter, Phase II Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Unresectable Recurrent or Metastatic Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 26 Feb 2024
At a glance
- Drugs Camrelizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 20 Jan 2024 Results assessing camrelizumab plus apatinib and SOX as first-line treatment in patients with alpha-fetoprotein-producing gastric or gastroesophageal junction adenocarcinoma presented at the 2024 Gastrointestinal Cancers Symposium.
- 19 Apr 2023 Planned number of patients changed from 117 to 64.
- 19 Apr 2023 Planned End Date changed from 31 Mar 2023 to 31 Dec 2024.